CytomX Therapeutics has developed activatable antibodies targeting Epidermal Growth Factor Receptor (EGFR) for cancer treatment. The patent covers a method involving specific antibody components and sequences for therapeutic use. GlobalData’s report on CytomX Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on CytomX Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. CytomX Therapeutics's grant share as of February 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Activatable antibody for treating cancer associated with egfr
A recently granted patent (Publication Number: US11890354B2) discloses a method for treating or delaying the progression of cancer associated with aberrant expression or activity of Epidermal Growth Factor Receptor (EGFR) in a subject. The method involves administering an activatable antibody that binds to EGFR when activated. This activatable antibody comprises specific structural components, including an antibody or antigen binding fragment that binds to EGFR, a masking moiety inhibiting binding in an uncleaved state, and a cleavable moiety functioning as a protease substrate. The patent also covers the conjugation of the antibody to various agents, such as toxins, dolastatin, auristatin, maytansinoid, calicheamicin, or detectable moieties, via a cleavable linker.
Furthermore, the patent encompasses various structural arrangements of the activatable antibody, including the incorporation of linking peptides, spacers, and specific amino acid sequences in the heavy and light chains. The method is applicable to a wide range of cancers, including breast, colorectal, lung, ovarian, and skin cancer, among others. By targeting EGFR with this unique activatable antibody, the patent aims to provide an effective treatment option for cancer patients with EGFR-related malignancies. The detailed structural requirements and conjugation possibilities outlined in the patent highlight the innovative approach towards cancer therapy, potentially offering a personalized and targeted treatment strategy for patients in need.
To know more about GlobalData’s detailed insights on CytomX Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
